Research progress on the mechanism and targeted therapy of Treg cells in colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2026.04.009

Abstract

Abstract:

Regulatory T cells (Tregs) are key immune components that mediate immunosuppression in the colorectal cancer tumor microenvironment (TME), facilitating tumor immune evasion and promoting tumor progression through various mechanisms. This article reviews the biological characteristics and intrinsic heterogeneity of Treg cells, as well as the mechanisms by which they mediate immunosuppression, including the secretion of inhibitory cytokines, nutrient competition, metabolic interference, and the formation of specific spatial niches. Furthermore, it summarizes the evolution and shift of Treg-targeted therapeutic strategies from simple depletion toward precise regulation, offering new directions for immunotherapy in colorectal cancer.

Key words: Colorectal cancer, Regulatory T cells (Treg cells), Immunosuppression, Tumor microenvironment, Immunotherapy

Jiayi Lin, Ying Huang. Research progress on the mechanism and targeted therapy of Treg cells in colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2026, 15(04): 356-360.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2026.04.009

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2026/V15/I04/356

References 36

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2]	Eng C, Yoshino T, Ruíz-García E, et al. Colorectal cancer[J]. Lancet, 2024, 404(10449): 294-310.
[3]	Wang F, Jin Y, Wang M, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial[J]. Nat Med, 2024, 30(4): 1035-1043.
[4]	Khudeir JF, Elkord E. Unmasking cancer’s silent saboteurs: T regulatory cells as therapeutic targets in immunotherapy[J]. Expert Rev Clin Immunol, 2025, 21(11): 1583-600.
[5]	Li D, Liu J, Yu L, et al. Integrated single-cell RNA-Seq reveals immunosuppressive mechanisms of Treg cell differentiation and tumor microenvironment interactions in colorectal cancer[J]. Cancer Med, 2025, 14(17): e71202.
[6]	Benoist C, Flavell RA, Mathis D, et al. The history and promise of Treg cells[J]. Immunity, 2025, 58(12): 2934-2939.
[7]	Estrada Brull A, Joller N. From chaos to control: nobel insights in regulatory T cells and immune tolerance[J]. Pflugers Arch, 2025, 478(1): 5.
[8]	Jugder BE, Park E, Du L, et al. Tissue-specific roles of regulatory T cells: mechanisms of suppression and beyond along with emerging therapeutic insights in autoimmune indications[J]. Front Immunol, 2025, 16: 1650451.
[9]	Lui PP, Cho I, Ali N. Tissue regulatory T cells[J]. Immunology, 2020, 161(1): 4-17.
[10]	Wang L, Liang Y, Zhao C, et al. Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential[J]. Signal Transduct Target Ther, 2025, 10(1): 345.
[11]	Sumida TS, Cheru NT, Hafler DA. The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases[J]. Nat Rev Immunol, 2024, 24(7): 503-517.
[12]	Hu W, Dolsten GA, Wang EY, et al. Temporal and context-dependent requirements for the transcription factor Foxp3 expression in regulatory T cells[J]. Nat Immunol, 2025, 26(11): 2059-2073.
[13]	Voß LC, Schmidt C, Harberts A, et al. Interferon regulatory factor 4 dose-dependently controls peripheral Treg cell differentiation and homeostasis by modulating chromatin accessibility in mice[J]. Front Immunol, 2025, 16: 1604888.
[14]	Peng Y, Tao Y, Zhang Y, et al. CD25: a potential tumor therapeutic target[J]. Int J Cancer, 2023, 152(7): 1290-1303.
[15]	Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy[J]. Cancer Cell, 2023, 41(3): 450-465.
[16]	Li D, Liu J, Yu L, Luo X, et al. Integrated single-cell RNA-Seq reveals immunosuppressive mechanisms of Treg cell differentiation and tumor microenvironment interactions in colorectal cancer[J]. Cancer Med, 2025, 14(17): e71202.
[17]	Tan SN, Hao J, Ge J, et al. Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39[J]. J Exp Med, 2025, 222(4): e20240445.
[18]	Lu Y, Li Y, Liu Q, et al. MondoA-thioredoxin-interacting protein axis maintains regulatory T-cell identity and function in colorectal cancer microenvironment[J]. Gastroenterology, 2021, 161(2): 575-591.e16.
[19]	You S, Li S, Zeng L, et al. Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity[J]. Cancer Cell, 2024, 42(8): 1415-1433.e12.
[20]	Li J, Wu C, Hu H, et al. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer[J]. Cancer Cell, 2023, 41(6): 1152-1169.e7.
[21]	Wang A, Huang H, Shi JH, et al. USP47 inhibits m6A-dependent c-Myc translation to maintain regulatory T cell metabolic and functional homeostasis[J]. J Clin Invest, 2023, 133(23): e169365.
[22]	Kumagai S, Koyama S, Itahashi K, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments[J]. Cancer Cell, 2022, 40(2): 201-218.e9.
[23]	Solomon I, Amann M, Goubier A, et al. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity[J]. Nat Cancer, 2020, 1(12): 1153-1166.
[24]	Tanaka A, Sakaguchi S. Targeting Treg cells in cancer immunotherapy[J]. Eur J Immunol, 2023, 53(1): e2250034.
[25]	Chen Q, Shen M, Yan M, et al. Targeting tumor-infiltrating CCR8⁺ regulatory T cells induces antitumor immunity through functional restoration of CD4⁺ Tconvs and CD8⁺ T cells in colorectal cancer[J]. J Transl Med, 2024, 22(1): 709.
[26]	Wen Y, Xia Y, Yang X, et al. CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells[J]. Trends Immunol, 2025, 46(2): 153-165.
[27]	Shen K, Song W, Wang H, et al. Decoding the metastatic potential and optimal postoperative adjuvant therapy of melanoma based on metastasis score[J]. Cell Death Discov, 2023, 9(1): 397.
[28]	Kang X, Li Y, Han Y, et al. Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer[J]. Mol Ther, 2025, 33(9): 4600-4617.
[29]	Guo R, Wang Y, Sun J, et al. Microwave ablation triggers OX40L-mediated disruption of TNFRSF4+ Treg immunosuppressive activity[J]. Front Immunol, 2025, 16: 1637317.
[30]	Bündgen G, Ulges A, Pietruschka J, et al. Polyamines regulate adaptive antitumor immunity by functional specialization of regulatory T cells[J]. Immunity, 2025, 58(8): 2019-2034. e11.
[31]	Shiri AM, Fard-Aghaie M, Bedke T, et al. Foxp3 + Treg-derived IL-10 promotes colorectal cancer-derived lung metastasis[J]. Sci Rep, 2024, 14(1): 30483.
[32]	Li Y, Singh N, Dong C, et al. Reprogramming intratumoral Treg cells by morpholino-mediated splicing of FOXP3 for cancer immunotherapy[J]. Sci Immunol, 2025, 10(110): eadr9933.
[33]	Long X, Zhang S, Wang Y, et al. Targeting JMJD1C to selectively disrupt tumor Treg cell fitness enhances antitumor immunity[J]. Nat Immunol, 2024, 25(3): 525-536.
[34]	Zhang J, Huang D, Saw PE, et al. Turning cold tumors hot: from molecular mechanisms to clinical applications[J]. Trends Immunol, 2022, 43(7): 523-545.
[35]	Kidani Y, Nogami W, Yasumizu Y, et al. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory[J]. Proc Natl Acad Sci USA, 2022, 119(7): e2114282119.
[36]	Zhang J, Sun L, Jiang L, et al. Regulation of CTLs/Tregs via highly stable and ultrasound-responsive cerasomal nano-modulators for enhanced colorectal cancer immunotherapy[J]. Adv Sci (Weinh), 2024, 11(22): e2400485.

Please choose a citation manager

Content to export